Print（PDF/139KB） May 12, 2021 Corporate
Notice of Change of Trade Name and Partial Amendment to Articles of Incorporation
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that our Board of Directors resolved at a meeting held on May 12, 2021, to submit a proposal to the Ordinary General Meeting of Shareholders scheduled for June 24, 2021 to change its trade name and partially amend its Articles of Incorporation, as described below.
1. Change of Trade Name
(1) Reason for Change
(1) Reason for Change
In October 2005, Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. merged and its trade name is Sumitomo Dainippon Pharma Co., Ltd. In 2021, the company celebrates the 16th year since the merger. During that time, we have globalized our business, entered new areas such as oncology, regenerative medicine and cell therapy, and frontier business, and taken on numerous challenges such as large-scale acquisitions and partnerships, the company has undergone a major transformation since the merger.
In these circumstances, in order for the company to grow continuously, we have decided to change the name of the company from "Sumitomo Dainippon Pharma" to "Sumitomo Pharma" with the aim of maximizing the use of the simple and globally accepted "Sumitomo" brand and changing toward a new business stage.
(2) New Trade Name
Sumitomo Pharma Co., Ltd.
(3) New Brand Logo
(4) Scheduled Date for Change
April 1, 2022
*This change in the trade name is subject to approval of the partial amendment to the Articles of Incorporation at the Ordinary General Meeting of Shareholders to be held on June 24, 2021.
2. Partial Amendment to the Articles of Incorporation
(1) Reason for Change
(1) Reason for Change
Article 1 (Trade Name) of the current Articles of Incorporation will be amended in order to change the trade name as stated in "1. Change of Trade Name" above.
(2) Details of Change
The details of the change are as follows
(Underlined parts indicate changes)
| Current Articles | Proposed Amendments |
|---|---|
| Chapter 1. General Rules (Trade Name) Article 1. The name of the Company shall be Dainippon Sumitomo Seiyaku Kabushiki Kaisha and, in English, its name shall be Sumitomo Dainippon Pharma Co., Ltd. |
Chapter 1. General Rules (Trade Name) Article 1. The name of the Company shall be Sumitomo Pharma Kabushiki Kaisha and, in English, its name shall be Sumitomo Pharma Co., Ltd. |
(3) Schedule
| Date of General Meeting of Shareholders to amend the Articles of Incorporation | ||
| June 24, 2021 (scheduled) | ||
| Effective date of the amendment to the Articles of Incorporation | ||
| April 1, 2022 (scheduled) | ||
3．Change in Trade Names of Subsidiaries
In conjunction with the change in the Company's trade name, the trade names of the Company's consolidated subsidiaries are scheduled to be changed as follows on April 1, 2022.
| Current trade name | New trade name |
|---|---|
| Japan | |
| DSP GOKYO FOOD & CHEMICAL Co., LTD. | Sumitomo Pharma FOOD & CHEMICAL Co., LTD. |
| Address: 20F, HERBIS OSAKA, 5-25, Umeda 2-chome, Kita-ku, Osaka | |
| Representative: Nobuyuki Hara, President and CEO | |
| DS Pharma Animal Health Co., Ltd. | Sumitomo Pharma Animal Health Co., Ltd. |
| Address: 10F, METLIFE Honmachi Square, 5-7, Honmachi 2-chome, Chuo-ku, Osaka | |
| Representative: Kazuhiro Takada, President and CEO | |
| DS Pharma Promo Co., Ltd | Sumitomo Pharma Promo Co., Ltd. |
| 33-94, Enoki-cho, Suita, Osaka | |
| Representative: Mitsuyuki Taniguchi, President and CEO | |
| DSP Associe Co., Ltd. | SMP Associe Co., Ltd. |
| Address: 6F, KT Building, 5-4, Hiranomachi 2-chome, Chuo-ku, Osaka | |
| Representative: Akiko Watanabe, President and CEO | |
| DSP Distribution Service Co., Ltd. | SMP Distribution Service Co., Ltd. |
| Address: 16-2, Yasakadai 3-chome, Suma-ku, Kobe, Hyogo | |
| Representative: Motoaki Matsushita, President and CEO | |
| DSP Business Partners Co., Ltd. | SMP Business Partners Co., Ltd. |
| Address: 6-8, Doshomachi 2-chome, Chuo-ku, Osaka | |
| Representative: Hajime Kinuta, President and CEO | |
| U.S. | |
| Sumitomo Dainippon Pharma America, Inc. | Sumitomo Pharma America Holdings, Inc. |
| Address: 84 Waterford Drive, Marlborough, MA 01752, U.S. | |
| Representative: Koji Ishida, Chair and CEO | |
| Sumitomo Dainippon Pharma Oncology, Inc. | Sumitomo Pharma Oncology, Inc. |
| Address: 640 Memorial Drive, Cambridge, MA 02139, U.S. | |
| Representative: Patricia S. Andrews, CEO | |
| China and Asia | |
| Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. | Sumitomo Pharma (Suzhou) Co., Ltd. |
| Address: No.115 QingQiu Street, SIP, Jiangsu Province, 215126 China | |
| Representative: Naoki Noguchi, Chairman and CEO | |
| Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. | Sumitomo Pharma Asia Pacific Pte. Ltd. |
| Address: 3 Fraser Street, #07-28 DUO Tower, Singapore 189352 | |
| Representative: Yoshitaka Koketsu, Managing Director | |
| Sumitomo Pharmaceuticals (Thailand) Co., Ltd. | Sumitomo Pharma (Thailand) Co., Ltd. |
| Address: Unit No. 1501, 15th Floor, Athenee Tower, 63 Wireless Road (Witthayu), Lumpini, Pathumwan, Bangkok 10330 Thailand | |
| Representative: Yukihide Mitsuyama, Managing Director | |
| Sumitomo Pharmaceuticals Taiwan Co., Ltd. | Sumitomo Pharma Taiwan Co., Ltd. |
| Address: 15F-2＆-3, No.62, Nanjing W. Rd., Datong Dist., Taipei City 103, Taiwan (R.O.C.) | |
| Representative: Toyohiro Yoneda, Managing Director | |
*There will be no change in the trade names of Sunovion Pharmaceuticals Inc., the companies of the Sumitovant Group, and S-RACMO Co., Ltd.
Inquiries from the Press